CAMX Stock Overview
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Camurus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr473.60 |
| 52 Week High | kr599.50 |
| 52 Week Low | kr220.00 |
| Beta | 0.84 |
| 1 Month Change | -4.78% |
| 3 Month Change | -4.78% |
| 1 Year Change | 112.38% |
| 3 Year Change | 127.15% |
| 5 Year Change | 557.78% |
| Change since IPO | 617.58% |
Recent News & Updates
Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects
Apr 19
Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality
Feb 22Recent updates
Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects
Apr 19Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality
Feb 22With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case
Feb 17Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected
Dec 20Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues
Nov 11We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve
Feb 22We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth
Apr 30We Think Camurus (STO:CAMX) Can Easily Afford To Drive Business Growth
Dec 09Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth
Sep 09Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth
Jun 10Shareholder Returns
| CAMX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -7.0% | -6.7% | -0.7% |
| 1Y | 112.4% | 60.6% | 8.7% |
Return vs Industry: CAMX exceeded the Swedish Pharmaceuticals industry which returned 65.2% over the past year.
Return vs Market: CAMX exceeded the Swedish Market which returned 8.1% over the past year.
Price Volatility
| CAMX volatility | |
|---|---|
| CAMX Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: CAMX's share price has been volatile over the past 3 months.
Volatility Over Time: CAMX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 213 | Fredrik Tiberg | www.camurus.com |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.
Camurus AB (publ) Fundamentals Summary
| CAMX fundamental statistics | |
|---|---|
| Market cap | kr27.29b |
| Earnings (TTM) | kr431.44m |
| Revenue (TTM) | kr1.72b |
63.3x
P/E Ratio15.9x
P/S RatioIs CAMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAMX income statement (TTM) | |
|---|---|
| Revenue | kr1.72b |
| Cost of Revenue | kr122.35m |
| Gross Profit | kr1.59b |
| Other Expenses | kr1.16b |
| Earnings | kr431.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 7.49 |
| Gross Margin | 92.87% |
| Net Profit Margin | 25.13% |
| Debt/Equity Ratio | 0% |
How did CAMX perform over the long term?
See historical performance and comparison